United Immunity's mission is to proactively and selectively target myeloid cells to deliver an innovative clinical experience to patients with cancer and infectious diseases. 

To achieve this, we are developing innovative nanoparticle and lipid nanoparticle (LNP) based on Cholesteryl Pullulan to selectively deliver therapeutic agents to macrophages, dendritic cells, as well as other myeloid cells such as tumor-associated macrophages (TAM), Kupffer cells in the liver, adipose tissue macrophages, and microglia. Our technology can be combined with various payloads including small molecules, mRNA, siRNA, DNA, peptides, proteins, and antibody fragments. United Immunity's Pullulan nanoparticle (PNP) and Pullulan LNP (P-LNP) are ideally suited for cancer and infectious disease vaccines, and have the potential for the treatment of fibrosis, inflammation, autoimmune, and metabolic diseases.

Our lead program, UI-102, applies our pullulan nanoparticle to precisely deliver a Toll-like receptor (TLR) agonist to M2-like tumor macrophages in order to modulate the tumor microenvironment from “cold (immune-suppressed)” to “hot (immune-activated)”. UI-102 aims to increase the efficacy of checkpoint inhibitors and other immunotherapy agents while significantly reducing safety risks associated with TLR agonism.
 
We are also using our technology to boost the effectiveness of T-cell therapies and generate in vivo CAR-macrophages.

United Immunity, Co., Ltd.

Org chart

Teams

Offices